Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinma Zhike Keli (marketed under the brand name Jinmaxing) is a Traditional Chinese Medicine (TCM) developed and manufactured by Chengde Yanfeng Pharmaceutical. It is primarily indicated for the treatment of acute tracheobronchitis, particularly in patients presenting with phlegm-heat obstructing the lungs. The formulation is a complex mixture of several herbal ingredients, including *Trollius chinensis* (Jinlianhua), *Viticis Fructus* (Manjingzi), *Armeniacae Semen Amarum* (Bitter Apricot Seed), and *Mori Cortex* (Mulberry Bark). According to TCM principles, the drug functions by clearing heat, resolving phlegm, and relieving cough and asthma. It was approved as a new TCM drug in China and is commonly administered as oral granules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jinma zhike keli.